AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New…
OCALA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune…